Monitor insider activity and future hiring trends; no immediate financial impact, but increasing headcount may signal expansion of clinical development efforts.
VOR drugs
VOR drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 24 $12.15entry
- T+1 · 8mo ago +6.50%α +5.94% · $12.94
- T+5 · 8mo ago +46.83%α +47.25% · $17.84
- T+20 · 7mo ago +26.09%α +17.19% · $15.32
- T+60 · 5mo ago +19.26%α +4.94% · $14.49
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Vor Bio granted stock options and RSUs to 8 new employees as inducement awards under its 2023 Inducement Plan. The awards cover 215,700 stock options and 46,235 RSUs, with exercise prices ranging from $7.95 to $24.11 per share, reflecting market closing prices on grant dates.
Key Facts
- Granted stock options for 215,700 shares and RSUs for 46,235 shares to 8 new employees
- Awards made in November 2025 and March 23, 2026 under Nasdaq Listing Rule 5635(c)(4) as material inducements
- Stock options have 10-year term, exercise price equals closing price on grant date ($7.95–$24.11)
- Options and RSUs vest over four years: 25% after 12 months, remainder monthly (options) or quarterly (RSUs)
- No financial performance data, revenue, or clinical updates included
Financial Impact
Minimal near-term financial impact; potential future dilution of ~0.5% based on ~261,935 total shares granted and $500M market cap
Risk Factors
- Future dilution from vesting of options and RSUs
- No performance-based vesting terms disclosed, compensation is time-vested only
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3260855 |
Track record
17 reports on VOR
3 of 4 bullish or bearish reports moved the stock their way by T+1. Best: +70.35% at T+60 after the Jun 8, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $18.97 Now $18.97 −0.00% settles Nov 18
- Nov 12, 20264d ago 8-K Neutral 5/10 Entry $19.32 to $19.42 Now $18.97 −1.81% ▲ +0.52% +0.88% vs SPY
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $18.66 to $19.88 Now $18.97 +1.66% ▲ +6.54% +6.23% vs SPY
- Oct 30, 202617d ago 424B5 Bearish 4/10 Entry $19.68 to $19.25 Now $18.97 +3.61% ▲ +2.19% +1.71% vs SPY
- Oct 30, 202617d ago Press Release Neutral 4/10 Entry $19.68 to $19.25 Now $18.97 −3.61% ▼ −2.19% −1.71% vs SPY
- Oct 22, 202625d ago Press Release Bullish 7/10 Entry $18.26 to $18.33 Now $18.97 +3.89% ▲ +0.38% −0.33% vs SPY
- Oct 5, 20266w ago Press Release Neutral 2/10 Entry $18.31 to $18.78 Now $18.97 +3.60% ▲ +2.57% +2.81% vs SPY
- Sep 29, 20266w ago Press Release Bullish 6/10 Entry $18.33 to $19.08 Now $18.97 +3.49% ▲ +4.09% +4.30% vs SPY
- Aug 11, 202613w ago Press Release Neutral 3/10 Entry $23.37 to $22.34 Now $18.97 −18.83% ▼ −4.41% −4.66% vs SPY
- Jul 9, 202618w ago 3 Neutral 2/10 Entry $19.14 to $18.03 Now $18.97 −0.89% ▼ −5.80% −5.03% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers